Skip to main content
Search results
https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/october-december-2023-potential-signals-serious-risksnew-safety-information-identified-fda-adverse
7 months ago -
Braftovi (encorafenib) Zelboraf (vemurafenib) Haemophagocytic lymphohistiocytosis
https://www.fda.gov/media/160597/download
over 5 years ago -
Urapidil 1 1273 Valpromide 1 1274 Vemurafenib 1 1275 Vindesine 1 1276 Voglibose
https://www.fda.gov/media/160470/download
over 2 years ago -
V600K mutation, in combination with vemurafenib. The drug is also currently being...rest period in combination with vemurafenib 960 mg twice daily. As ...
https://www.fda.gov/media/160471/download
over 2 years ago -
V600K mutation, in combination with vemurafenib. The drug is also currently being...rest period in combination with vemurafenib 960 mg twice daily. As ...
https://www.fda.gov/media/160472/download
over 2 years ago -
V600K mutation, in combination with vemurafenib. The drug is also currently being...rest period in combination with vemurafenib 960 mg twice daily. As ...
https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools
7 months ago -
Inc.) Melanoma - Tissue Zelboraf (vemurafenib) NDA 202429 BRAF V600E P110020 (08/17/2011)...206192 in combination with Zelboraf (vemurafenib) NDA ...
https://www.fda.gov/media/160992/download
over 2 years ago -
V600K mutation, in combination with vemurafenib. Reference ID: 5020200 2. Regulatory...V600K mutation, in combination with vemurafenib. A Proposed ...
https://www.fda.gov/media/177481/download
8 months ago -
Tafinlar® (dabrafenib) or Zelboraf® (vemurafenib) BRAF V600E and V600K Mekinist®...(cobimetinib) in combination with Zelboraf® (vemurafenib) Breast ...
https://www.fda.gov/media/71494/download
5 months ago -
SELEGILINE HYDROCHLORIDE ZELBORAF, VEMURAFENIB ZELSUVMI, BERDAZIMER SODIUM ZEMBRACE
https://www.fda.gov/media/160993/download
over 2 years ago -
V600K mutation, in combination with vemurafenib. The recommended dose is 60 mg orally...V600K mutation, in combination with vemurafenib. The Applicant ...
https://www.fda.gov/media/171345/download
over 1 year ago -
Inc.) Melanoma - Tissue Zelboraf (vemurafenib) NDA 202429 BRAF V600E P110020 (08/17/2011)...206192 in combination with Zelboraf (vemurafenib) NDA ...
https://www.fda.gov/media/178811/download
over 2 years ago -
...increases severe ZELBORAF VEMURAFENIB VEMURAFENIB Arrhythmia wp most QT prolongation
https://www.fda.gov/media/177768/download
8 months ago -
...8 (HF) 7.4-7.8 (HF) without food Vemurafenib 5 (HF) 2.5 (HF) regardless of food
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-certain-patients-erdheim-chester-disease-rare-blood-cancer
over 4 years ago -
FDA expands approval of Zelboraf (vemurafenib) to treat certain adult patients...expanded the approval of Zelboraf (vemurafenib) to include the ...
https://www.fda.gov/media/120721/download
almost 3 years ago -
...is the phase 2 trial evaluating vemurafenib in multiple nonmelanoma cancers...Tabernero, and J Baselga, 2015, Vemurafenib in Multiple Nonmelanoma ...
https://www.fda.gov/media/174295/download
about 1 year ago -
...inhibitor VANDETANIB kinase inhibitor VEMURAFENIB kinase inhibitor ZANUBRUTINIB kinase
https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems
6 months ago -
...vardenafil 3A4 sensitive substrate vemurafenib 1A2 moderate inhibitor 2D6 weak
https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
10 months ago -
Contraindications, Warnings and Precautions Vemurafenib (1) Oncology BRAF Indications and... Patient Counseling Information Vemurafenib (2) Oncology ...
https://www.fda.gov/media/176893/download
9 months ago -
...including dabrafenib plus trametinib, vemurafenib plus cobimetinib, encorafenib plus...atezolizumab plus cobimetinib plus vemurafenib, are approved ...
https://www.fda.gov/media/129886/download
almost 3 years ago -
V600K mutation, in combination with vemurafenib. COTELLIC is not indicated for treatment
